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ABSTRACT
The Spacecraft Maximum Allowable Co_,,centrations
(SMACs) are exposure limits for airborne chemicals used by
the National Space and Aeronautics Administration (NASA)
in spacecraft. The aim of these SMACs is to protect the
spacecraft crew against adverse health effects and
pefformanace decrements that would interfere with mission
objectives. Because the 1-hr and 24-br SMACs are set for
contingencies, minor, reversible toxic effects that do not affect
mission objectives are acceptable. The 7-day, 30-day, or 180-
day SMACs are aimed at nominal operations, so they are
established at levels that would not cause noncarcinogenic
toxic effects and more than one case of tumor per 1000
exposed individuals over the background. The process used
to set the SMACs for carbon monoxide (CO) is described to
illustrate the approach used by NASA.
After the toxicological literature on CO was reviewed, the
data were summarized and separated into acute, subchronic,
and chronic toxicity data. CO's toxicity depends on the
formation of carboxyhemoglobin (COHb) in the blood,
reducing the blood's oxygen-carrying capacity. The initial
task was to estimate the COHb levels that would not produce
toxic effects in the brain and heart. Then the Coburn-Forster-
Kane (CFK) equation was used to calculate the CO exposure
concentration that would lead to a no-effect COHb level upon
exposure for a given duration (1 hour to 180 days) and that
CO concentration was selected as the SMAC. The 1-hr and
24-hr SMACs were set at 55 ppm and 20 ppm, respectively, to
prevent central nervous system (CNS) impairment at COHb
of 3%. Ten ppm was selected to be the 7-day, 30-day, and
180-day SMACs to ensure that the COHb level would not
exceed 1.6%, which would protect against abnormal heart
rhythms and CNS impairment.
1. INTRODUCTION
Inhalation exposures to some chemicals may lead to toxic
effects that impair the health or performance of the exposed
subjects. To provide a safe environment for the astronauts in
spacecraft, NASA has established SMACs for 190
chemicals (l) . The SMACs are exposure limits that, ifnot
exceeded, would prevent health injuries and the crew's
performance decrement due to exposures to airborne
chemicals. The official SMACs were set, without
documentation, about 20 years ago and currently they are
designated as 7-day SMACs for space shuttle missions.
There are two reasons why the official 7-day SMACs need to
be revised: I) availability of new toxicity data for most of
these chemicals and 2) scientists have a better understanding
of toxicologic principles. In addition to revision of the 7-day
SMACs, a range of SMACs is necessary to a adequately cover
all potential exposures associated with nominal operations,
contingency events and extended duration missions. The
Johnson Space Center (JSC) Toxicology Group has decided
that this range should include SMACs for 1 hr, 24 hr, 30 days,
and 180 days. The 7-day, 30-day, and 180-day SMACs are
designed for nominal operations, so they are set at levels that
would not cause noncarcinogenic toxic effects. For
carcinogens, the 7-day, 30-day, and 180-day SMACs are
established so that the risk of getting tumors is no more than
one in a thousand above the background level. In contrast, the
1-hr and 24-hr SMACs are aimed at contingency situations.
Therefore, minor, reversible toxic effects are acceptable
provided that they do not prevent the spacecraft crew from
achieving the mission objectives. Examples of these
acceptable toxic effects are mild mucosal irritation and
headaches. Compared with the longer-term SMACs, the l-hr
and 24-hr SMACs are, therefore, sometimes set at levels
relatively higher than what the differences in exposure
duration would suggest.
The JSC Toxicology Group has embarked on the project of
setting new l-hr, 24-hr, 7-day, 30-day, and 180-day SMACs
for the 190 chemicals in the current official list and a number
of new chemicals. The new SMACs will be used in support
of the Space Shuttle missions and future Space Station
Freedom missions. In addition, some of the new SMACs will
serve as the design criteria for the air revitalization subsystem
of the Environment Control and Life Support System and for
air-quality monitoring equipment of the Environmental Health
System in the Space Station Freedom. Overly conservative
SMACs must be avoided because these could cause these
systems to be designed with unnecessary weight or power
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burden.
Establishing new SMACs proceeds in three stages. First, the
JSC Toxicology Group sets interim SMACs based on its
understanding of the chemical toxicity and state-of-the-art
toxicologic principles, assisted by a guideline provided by the
National Research Council's Committee on Toxicology
(NRC-COT). The interim SMACs and their rationale are,
then, reviewed by the NRC-COT. Finally, the JSC
Toxicology Group would, if necessary, revise the interim
SMAC values and the documentation according to the NRC-
COT's comments. The interim SMACs become official after
this review process.
This paper describes the JSC Toxicology Group's approach in
setting the new SMACs by using carbon monoxide as an
example. CO is acolorless and odorless gas (2). It is
produced both endogenously and exogenously. In the body,
CO is produced at a rate of 0.4 ml/hr via catabolism of
hemoglobin and nonhemoglobin heme (3). The incomplete
oxidation during thermodegradation of materials containing
carbon in an atmosphere containing oxygen is an exogenous
source of CO. For instance, CO could be produced when gas
stoves and furnaces are in use. Smoking is another common
indoor exogenous source of CO (4), which has been measured
in main-stream cigarette smoke at 40,000-50,000 ppm (5).
(4)The primary outdoor source of CO is automobile exhaust .
In the 1960's and 1970's, CO concentrations of 20-30 ppm
were commonly detected on expressways in major U.S. cities
and on a busy street inside London during rush hours, with
(4 5)peak concentrations exceeding 100-300 ppm , .
Inside spacecraft, there is no known use of carbon monoxide.
However, CO metabolically produced by the astronauts may
accumulate in the cabin. Of course, a large amount of carbon
monoxide may be produced if there were a thermodegradation
accident in the cabin. Therefore, carbon monoxide could be a
threat to the crew's health and SMACs for carbon monoxide
are critically needed for crew protection.
2. GENERAL APPROACH IN SETrlNG SMACs
2.1. Literature Searches
2.1.1. Nonbiological Literature
The SMAC-setting process begins with a literature search on
the important physical and chemical properties of the
chemical. Information gathered typically includes the
Chemical Abstract registry number, chemical structure,
molecular weight, boiling point, melting point, and vapor
pressure. The Chemical Abstract registry number is to
facilitate the toxicological literature search. The chemical
structure sometimes gives a preliminary idea of the
chemical's toxicity and it, thus, also helps to plan the
toxicological literature search. The molecular weight is used
in the conversion of airborne concentration units from mg/m 3
to ppm or vice versa.
The boiling and melting points determine the potential
physical form of the chemical in the spacecraft. The physical
form, in turn, determines the exposure pathway. For instance,
if the chemical exists as a solid, the potential exposure routes
are ingestion, cutaneous contact, and inhalation as a dust.
Since ingestion can be avoided if care is exercised by the
astronauts and cutaneous contacts with a solid usually will not
present a systemic toxic hazard, the most significant exposure
route of a solid is by inhalation, provided that the solid exists
as particulate. On the other hand, if the chemical is a liquid at
room temperature and normal ambient pressure, it may be
inhaled as a vapor, plus there may be cutaneous exposures.
Of course, if the chemical exists as a gas, inhalation would be
the primary route of exposure.
The vapor pressure gives an indication of the potential for the
chemical to be inhaled. For example, if the vapor pressure is
low, the liquid may have to be aerosolized before it would
present a significant inhalation hazard. However, if the liquid
is highly volatile, inhalation in the vapor form would be the
most likely scenario. Although solid or liquid chemicals will
float in air in microgravity, presenting a potential to be
ingested, the chance of such an event occurring to a
significant extend is very slim. Consequently, oral exposures
are not considered in setting SMACs.
2.1.2. Biological Literature
The second step is to thoroughly search the literature on the
toxicological properties of the chemical, using the
computerized data bases of the National Library of Medicine.
The particular data bases routinely searched are the
TOXLINE, TOXLIT, IRIS, and the Hazardous Substances
Data Bank. Occasionally, Chemical Abstracts is also
searched. After an initial screen of the publication titles,
publications of interest are selected and their abstracts are
then extracted from the data bases. These abstracts are read
and the key publications are obtained via our library.
2.1.3. Literature Selection Criteria
The selection criteria for publications include the type of
study system used by the investigators, the species of the
study subjects, and the exposure route used in the study.
These criteria all could influence the usefulness of the
publication in setting SMACs.
2.1.3.1. Study System as a Selection Criterion
Except for the studies of the effect of the chemical on genetic
materials, the literature on the chemical's effect on an in vitro
system is routinely not reviewed. In vitro systems are systems
in which the experiments are conducted with tissues or cells
isolated from the body and maintained in a growth media in a
petri dish or flask. The reason in vitro studies are not relied
upon is three-fold. First, not all the cell types are present in
an in vitro system, so the response seen in the system may be
different from the response seen in the body. Second, when
613
the tissues or cells are maintained in a growth media, the
tissues or cells may change their biological characteristics so
that they react to the chemical differently than they would
have in the body. Third, it is difficult to convert the chemical
concentration used in the growth media to an inhalation
exposure concentration. Due to the artificial nature and all the
uncertainties on the representativeness of the results, i!) vitro
data play a very small role in setting SMACs.
2.1.3.2. Species as a Selection Criterion
Publications dealing with the toxic effects on plants and
nonmammalian animals are usually ignored because the
meaning of a toxic effect in plants or nonmammalian animals
is doubtful for astronauts, the subjects protected by the
SMACs.
2.1.3.3. Exposure Route as a Selection Criterion
In terms of the exposure route, there is little emphasis on
studies done using oral or cutaneuous routes or studies in
which the chemical was administered into the experimental
subject by injection. This approach is taken because, to
estimate a safe exposure limit for an airborne chemical, the
toxic effects by inhalation exposures are most relevant.
Although there are ways to estimate the equivalent inhalation
exposure concentrations for exposures by noninhalation
routes, there are controversies on the accuracy of the methods.
Some toxicologists even take the position that extrapolation of
toxicological data from a noninhalation route of exposure to
inhalation is invalid. However, if there is no toxicity
information on a chemical given by inhalation and a "safe"
airborne exposure limit is definitely needed, then sometimes
we may calculate an inhalation exposure concentration that is
somewhat equivalent to a dose of the chemical given by
injection or oral administration. The calculation assumes that
the chemical is absorbed to the same degree regardless
whether the exposure is by an oral or inhalation route and that
the absorption rate stays constant during the entire duration of
an inhalation exposure. The equivalent inhalation exposure
concentration is calculated using the typical minute volume of
an average adult. Even though these assumptions may not be
precisely correct, they tend to err on the conservative side, so
the extrapolation method is considered an acceptable means of
calculating the equivalent inhalation exposure concentration
as a last resort.
2.1.4. Other Types of Information Gathered
In addition to reviewing the literature on the toxicity of the
chemical, the literature on the absorption, metabolism (how
the body modifies the chemical), excretion, pharmacokinetics
(how fast the body handles the chemical), and mechanism of
toxicity (how the chemical causes toxic effects in the body) is
scrutinized. Such data are important in setting the SMACs,
but they are typically incomplete.
Absorption and excretion information is useful. Knowing
how well the body takes in the chemical and how well it
eliminates the chemical provides a better understanding of the
biological fate of the chemical, which in turn helps in the
interpretation of the toxicity data.
Metabolism information is important because some chemicals
are toxic after the body converts the chemicals into
metabolites which are more toxicologically active than the
parent chemicals. For these chemicals, the SMACs should be
set according to the potential level of the active metabolite in
the body and not according to that of the parent chemical.
Knowing the pharmacokinetics of the chemical could provide
us a way to estimate the level of the chemical at the target site
in the body at different times during or after an inhalation
exposure. Because the toxicity depends on the chemical level
at the target site, the estimates of that level with time allows
the proper adjustments of toxicity data from a certain
exposure duration in a study to the duration for which the
SMAC is designed.
2.2. Evaluation of the Toxicological Literature
Evaluation of the information on toxicity, metabolism,
pharmacokinetics, excretion, and mechanism of toxicity
provides a thorough understanding of the toxic nature of the
chemical in the biological system. They are of value in
making predictions on the nontoxic exposure concentrations
for different exposure durations.
2.2.1. Species
Because a chemical's toxicity, metabolism, pharmacokinetics,
excretion, and mechanism of toxicity could vary depending on
the species of the exposed subject, it is important that SMACs
should be set relying on data gathered from human subjects
whenever possible. Therefore, in evaluating the toxicological
literature, emphasis is placed on human studies. Due to
ethical reasons, many types of toxicological studies are not
conducted on human subjects. As a result, we sometimes
have to rely on toxicological data gathered in studies using
laboratory animals. Among the data gathered from laboratory
animals, more weight is given to data in nonhuman primates
because of the physiological and anatomical similarities of
monkeys, baboons, etc., to man. For data gathered in
nonprimate animal species, a slight preference is given to
larger animal species, e.g., the dog, than rodents. The reason
is that the human physiology and anatomy are more analogous
to that in larger species.
2.2.2. Exposure Duration
Because the pattern of toxicity of a chemical could vary with
the exposure duration, the toxicity data are categorized into
acute, subchronic, and chronic. Acute toxic changes are
adverse effects produced by the chemical after a single, short-
term exposure. Adverse effects on the body caused by the
chemical after an exposure lasting almost a normal life span
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are termed chronic toxic changes. Subchronic toxicity is the
toxic effect produced by a chemical exposure that lasts
between a short:term exposure and a near life-time exposure.
Actually, the transition from acute toxicity to subchronic
toxicity sometimes is imprecise because the definition of
subchronic toxicity is not very specific. Therefore, some
toxicologists have added a quantitative criterion into the
definition. They define subchronic toxicity as the toxic effect
seen after the subject has been exposed to the chemical for
less than a life time, but more than 10% of the life time.
Because 10% of a life span of 70 year is too long a time
relative to the exposure durations of the SMACs, here we
have chosen the less specific definition of subchronic toxicity.
We have opted for a definition that any exposure lasting for
about a week to almost a life time is subchronic.
Because the toxicity of a chemical could differ according to
the exposure duration, the categorization of the toxicity
information found in the literature into acute, subchronic, and
chronic types is important for the setting of SMACs of
different duration. Ideally, a SMAC should be set using
toxicological data generated in a study in which the exposure
duration was similar to the exposure duration that the SMAC
is intended to be used. So the 1-hr and 24-hr SMACs should
be set using acute toxicological data. By the same token,
subchronic toxicological data should be used to establish the
7-day, 30-day, and 180-day SMACs.
Chronic toxicological data usually yield information on the
carcinogenicity of the chemicals. Tumors are thought to be
produced via a different process than the production of
noncarcinogenic endpoints, e.g., liver injury. The setting of
SMACs based on the carcinogenesis of a chemical,
consequently, involves a different approach than the setting of
SMACs based on noncarcinogenic endpoint. Such an
approach will be described separately below.
2.2.3. Data Quality
To make the SMACs meaningful, it is obvious that the
SMACs should be established based on good quality data. In
evaluating the literature, attention is always placed on the data
quality. The factors considered in assessing the data quality
are the number of test subjects, the homogeneity of test
subjects, the way the exposure concentration was determined
in the study, the purity of the chemical used, the method of
detecting the toxic changes, and the way study results were
analyzed.
2.2.3.1. Number of Test Subjects
The study has to use a sufficient number of test subjects in
order to make the response detected in the study
representative of what would be seen in a population. The
sample size is important because, unlike physical or chemical
systems, biological systems could have quite a large degree of
variability due to differences in the genetic makeup. If the
data were gathered in a study with only a few human subjects,
the average response in these subjects most probably would
not be predictive of how other human beings, such as
astronauts, would react to the chemical. As a result, SMACs
set on the results of such a study are of doubtful value.
2.2.3.2. Homogeneity of Test Subjects
While the homogeneity of the test subjects used would not, by
itself, eliminate a study from being relied upon in setting
SMACs, it is still an important criterion. Because a test
subject's response to a chemical is influenced by many factors
related to the subject, it is important that the study subjects are
very similar anatomically and physiologically so that any
changes seen in the study could be ascribed to the chemical
exposure alone. Therefore, we prefer studies in which the
composition of the exposed group is very similar to that of the
control (nonexposed) group. Confounding factors, such as
existing disease state and smoking habit, that may influence
the response to the chemical, should be eliminated to the
extent possible. Given the impossibility of conducting a study
with a perfectly homogeneous human population, these
confounding factors should be randomized evenly between
the exposed and the nonexposed group. In laboratory animal
studies, the control of confounding factors is easier. So
among animal studies, an emphasis should be placed on
studies with healthy animals of similar age and body weight.
2.2.3.3. Measurement of Exposure Concentrations
Since the SMACs are set based on the toxic effects detected at
some specific exposure concentrations in studies in the
literature, it is important that the reported exposure
concentrations were accurate. Consequently, during the
literature evaluation, attention is paid to the concentration
measurement method. Questions usually asked include
whether the exposure concentration was measured analytically
or estimated from the amount of chemical introduced into the
exposure system. If the concentration was measured
analytically, we would determine if the analytical method is
specific for the chemical and if it is sensitive enough in the
range of the study concentrations.
2.2.3.4. Chemical Purity
An issue related to the method of determining the exposure
concentration is the purity of the chemical used in the study.
To eliminate exposures to chemicals other than the study
chemical as a confounding factor, preference is given to
studies in which the subjects were exposed to only one
chemical. That means in experimental studies, the study
chemical used should be of high purity (over 99% preferably
and at least 95%). Attention should be paid to the identities
and relative quantities of the impurities. In epidemiological
or occupational studies, it is difficult to control the exposure,
so there is no exact purity requirement. For this reason,
experimental human studies are preferred over
epidemiological or occupational studies.
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2.2.3.5. Detection Method of the Toxic Effect
Another important evaluation criterion is the method used to
detect the toxic effect. Other than studies investigating
chemical-induced headache and mucosal irritation, objective
methods are given more weight than subjective methods to
avoid biases of the investigators. If the study involves human
subjects, it is prefered that the subjects did not know whether
they were being exposed to the chemical or just air. If the
method of detecting the toxic effect involves the
investigators' judgment, a double blinded study is prefered.
Other factors considered include whether the method is
specific for the toxic effect to be detected, the method's
sensitivity and accuracy, and the reproducibility of the
method. It is obvious that the specifity and accuracy of the
endpoint detection method are important because the
measured change should reflect the real toxic effect. By the
same token, any lack of measurable changes should represent
a real absence of toxic effect, so the detection method must be
sensitive. Finally, the method's reproducibility is important
in ascertaining that the measured change was caused by the
chemical and not due to any aberrant behavior of the detection
method.
2.2.3.6. Data Evaluation in the Study
To ensure that the investigators drew the correct conclusion in
the study, it is important that the data were analyzed properly.
To deal with biological data that could vary tremendously, the
use of statistics is imperative. We routinely check whether
the toxic changes reported were based on suitable statistical
analyses.
3. SMAC Setting Procedure
The general procedure is to set a maximum allowable
concentration (MAC) for each toxic endpoint meaningful for
the exposure duration of interest and select the lowest MAC,
among those of different endpoints, as the SMAC for that
duration. The way to set a MAC for carcinogenesis is
different from that for noncarcinogenic endpoints. The ways
for setting the two types of MACs are described separately.
3.1. MAC based on noncarcinogenic endpoint
The SMAC for an exposure duration is defined as the
maximum exposure concentration that causes no or practically
no toxicity for that exposure duration. The MAC for a
particular toxic endpoint is, then, the maximum exposure
concentration that would not cause that toxic effect. It is
believed that the higher the exposure concentration the greater
the toxicity. So, from the study results, we are interested in
the maximum exposure concentration that failed to produce a
specific toxic effect to a practical extent and such a
concentration is called a no-observed-adverse-effect-level or
NOAEL. To obtain the NOAEL for a noncarcinogenic
endpoint, the acute, subchronic, and chronic toxicity data are
separated. In each of these three categories, the data are
further separated according to the toxic endpoint. The highest
exposure concentration known not to cause a particular
noncarcinogenic toxic effect is identified as the NOAEL for
that effect.
3.1.1. Safety Factors
Due to uncertainties inherent in some studies, to err on the
conservative side, the NOAEL for a particular
noncarcinogenic endpoint is sometimes divided by safety
factors to arrive at the MAC. If the study used animals as the
test subjects, an interspecies extrapolation factor may be used.
If the study was of an exposure duration different from the
exposure duration of the SMAC, a time-adjustment factor is
applied. The time-adjustment factor is based on the Haber's
rule that the product of the exposure concentration and
exposure time is approximately constant. It should be pointed
out that the Haber's rule is not universally applicable.
Another situation in which a safety factor is applied is when
the chemical's toxic effect is similar to a biological effect
induced by microgravity. For instance, microgravity has been
known to reduce the red blood cell mass and to cause minor
irregular heart rhythm in astronauts during a mission (7'8). If
a chemical also produces a change in the red blood cell or
heart rhythm, a microgravity-related safety factor is usually
applied on the NOAEL to derive the MAC.
3.2. MAC based on carcinogenesis
Most carcinogens have been shown to act by damaging the
genetic material of the body and these are called genotoxic
carcinogens. Because there is a better understanding of
genotoxic carcinogens, the setting of MAC based on
carcinogenesis is described using genotoxic carcinogens as
examples. The current thought is that there is no such thing as
a NOAEL for the tumor response to genotoxic carcinogens.
That means even a single molecule of genotoxic carcinogen in
the body could theoretically lead to tumor development. The
JSC Toxicology Group has adopted 1/1000 as an acceptable
tumor risk. So the maximum concentration of a carcinogen
that could produce one case of tumor, in excess of the
background, in 1000 exposed individuals is the MAC for that
carcinogen.
The MAC based on carcinogenesis is usually generated from
chronic test data in laboratory animals. Using these data, the
U.S. Environmental Protection Agency or the NRC-COT
calculated, with the linearized multistage model, the upper
95% confidence limit of the life-time exposure concentration
that yields an excess tumor risk of 1/1000. We obtain the
MAC based on carcinogenesis by taking that upper
confidence limit and adjust, with the method of Crump and
Howe (9), for the difference in exposure duration between the
continuous, life-time exposure of the EPA or NRC-COT value
and the exposure duration for which the SMAC is designed.
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4. Setting the SMACs for Carbon Monoxide
The setting of the carbon monoxide's SMACs will be used to
illustrate the procedure of establishing SMACs described
above.
4.1. General Biological Information on CO
Carbon monoxide is absorbed rapidly in the lung at a rate of
about 25 8 ml/min x mm Hg (10_. Carbon monoxide's
elimination half-life is 4-5 hours in resting subjects when
breathing ambient air (4).
As mentioned earlier, an understanding of the mechanism of
toxicity is very useful in setting SMACs. Information on the
mechanism of toxicity of carbon monoxide indicates that,
unlike most chemicals, the exposure concentration of carbon
monoxide together with the exposure duration is not the best
way to characterize carbon monoxide's toxic potential.
Carbon monoxide acts by reversibly binding to the heme
group in hemoglobin, forming carboxyhemoglobin
(COHb) (12). As a result, less oxygen will be carried by blood
to tissues during carbon monoxide inhalation. That means
organs, such as the heart and the brain, having a critical need
for oxygen would be the major target organs for carbon
monoxide poisoning. Indeed, data indicate that carbon
monoxide's toxicity is manifested primarily on its effects on(4)the heart and the brain . However, it should be pointed out
that not all COHb levels are harmful to the health. For
instance, the normal metabolism of heine generates carbon
monoxide inside the body, leading to a COHb level of 0.4-
0.7%, which does not result in adverse effects (4).
Due to the fact that carbon monoxide's toxicity is correlated
with the COHb level in the blood, the SMACs were set
according to safe COHb levels and the toxicity data were
reported in terms of the COHb levels. The COHb level will
rise with time as an individual inhales carbon monoxide and it
would reach a plateau within 24 hours (13). The resulting
COHb level of a carbon monoxide can be calculated using the
Coburn-Forster-Kane (CFK) equation (13).
4.2. Toxicity Information on Carbon Monoxide
The most important information for the establishment of
SMACs is the information on the toxic effects of the
chemical. To facilitate the setting of short-term and long-term
SMACs, toxicity information on carbon monoxide was
separated into three categories: acute, subchronic, and
chronic.
4.2.1. Acute Toxicity
This subsection summarizes the toxicity of carbon monoxide
in humans after an exposure ranging from several minutes to
8 hours. A COHb level of 70% is lethal, while 50-60% leads
(4)to coma and convulsions . Headache, nausea and vomiting
(14 i5)are detected are detected at 15-40% COHb , . Increased
frequencies of ventricular remature de olarization were seen
• P 1 P
in coronary patients at 6% COHb(6). A COHb level of 5%
is known to increase reaction time and impair hand-eye
coordination(l 1,17). Finally, carbon monoxide reduces the
maximal exercise duration at 3.4% COHb(I 8).
4.2.2. Subchronic Toxicity
This subsection summarizes the toxicity produced by carbon
monoxide exposures la3ting longer than one day. A
continuous exposure of humans to carbon monoxide for 7 or 8
days resulting in 2.4% COHb has been shown to produce
heart rhythm changes (19). New York employees working in a
tunnel with, on the average, 38 ppm carbon monoxide, as well
as other automobile exhaust pollutants, showed a higher
mortality from arteriosclerotic heart disease (20). However,
whether subchronic carbon monoxide exposures cause
arteriosclerotic heart diease is still not certain.
There are a lot of data on carbon monoxide's subchronic
toxicity gathered in laboratory animals, but only the more
important data will be described here. As discussed above,
carbon monoxide intoxication primarily produces toxicity on
the brain and the heart. However, animal studies
demonstrated that, in subchronic exposures, carbon monoxide
could also cause increases in hemoglobin concentration in the
blood. For instance, a continuous, 6-month exposure of dogs
to 50 ppm carbon monoxide, which is equivalent to 7.3%
COHb, increased the hemoglobin concentration by 12%, but
it did not cause any changes in theEKG (21). Similarly, a
continuous, 90-day exposure of rats to 96 ppm carbon
monoxide (equivalent to 7.5% COHb) increased both the
hemoglobin concentration and the hematocrit (22).
The increases in hemoglobin and red blood cells probably
represent an adaptation of the body to the subchronic
deficiency of oxygen supply to tissues. It should be noted,
however, that there are species differences in this adaptive
response. No increases were seen in monkeys exposed to 66
ppm of carbon monoxide, reaching a COHb level of 7.4%, for
2 years (23). It took a much higher level of carbon monoxide
exposure for such an adaptive response to occur in the
monkey. A continuous exposure of monkeys to 200 ppm
carbon monoxide (equivalent to 16 to 20% COHb) increased
the hematocrit and hemoglobin level (22). Because humans
are biologically closer to monkeys than to the dog or rat and
because astronauts are not expected to encounter high levels
of carbon monoxide for a long time, this adaptive response of
the body toward subchronic carbon monoxide most likely
would not occur in the astronauts. As a result, the adaptive
response was not considered in setting the carbon monoxide
SMACs.
4.2.3. Chronic Toxicity
There are no data on the toxic effects of a carbon monoxide
exposure lasting almost the normal life span of an adult.
617
4.3. Rationale Used to Set the Short-term SMACs
In an acute carbon monoxide exposure, the lowest COHb
level that has been found to adversely affect the body is 3.4%,
which reduced the maximal exercise duration by 5% in human
volunteers (18). Since a mere 5% reduction in the maximal
exercise duration would not significantly impair the astronauts
in an emergency, the exercise effect of 3.4% COHb is
considered acceptable in short term. Therefore, the second
lowest toxic COHb level is chosen to be the criterion for
setting the l-hour and 24-hour SMACs.
A short-term exposure to carbon monoxide, yielding a COHb
level of 5%, is known to cause CNS impairment, such as an
impairment of hand-eye coordination and an increase in
reaction time (17). The short-term SMACs should be set to
prevent CNS impairment because CNS impairment would
interfere with the astronauts' ability to deal with an
emergency. The task is to estimate a COHb level that would
not cause CNS impairment. Because 5% COHb appears to be
n h n"(l 1) anthe threshold for causing CNS impairme t in uma _ d
because an l-hour exposure to carbon monoxide at the 1-hour
National Ambient Air Quality Standard would yield a COHb
level of about 3% in exercising subjects (6), the 1-hour and 24-
hour SMACs are set at a level that would produce no more
than 3% COHb in the astronauts. Using the hemoglobin
concentration determined inflight during the Skylab
missions (24), the 1-hour and 24-hour carbon monoxide
exposure concentrations that would yield a 3% COHb were
calculated with the CFK equation (13). The 1-hour and 24-
hour exposure concentrations were calculated to be 55 ppm
and 20 ppm, respectively. The l-hour and 24-hour SMACs
were set at 55 ppm and 20 ppm, respectively.
4.4. Rationale Used to Set the Long-term SMACs
microgravity on the heart. The reason is that the 7-day
SMAC is based on the 8-hour National Ambient Air Quality
Standard, which was designed to protect the general
population and the astronauts are much healthier than the
in firmed or the aged in the general population.
There are no human data on carbon monoxide's toxicity for an
exposure lasting longer than 8 days. The subchronic data
gathered in laboratory animals (21-23) were not relied upon in
setting the 30-day and 180-day SMACs because the most
sensitive endpoints, i.e., CNS impairment and cardiac
arrhythmias, were not reliably determined in these studies.
The target COHb level of the 7-day SMAC of 1.6% was
chosen to be the target COHb level for the 30-day and 180-
day SMACs. A COHblevelof 1.6% should provide a
sufficient safety margin for the astronauts in a 30- or 180-day
carbon monoxide exposure. The reason is that 1.6% is not
much higher than the COHb level of 0.7-1.0% measured in
nonsmokers (26) and it is also lower than the COHb level of
3% or 4-5% in smokers (27'28). With the CFK equation, the
30-day and 180-day SMACs were calculated to be both 10
ppm(l'3)
5. CONCLUSION
After reviewing information on the toxicity, absorption,
metabolism, and pharmacokinetics of a chemical, the
toxicologist must systematically sort the data and identify the
toxic endpoints that a SMAC must protect against. By
applying toxicological principles to the appropriate data on
the toxic endpoints, the safe exposure concentration is then
estimated for a given exposure duration and such a
concentration is the SMAC for that exposure duration. This
paper demonstrates the approach using carbon monoxide as an
example.
In setting the 7-day SMAC, the toxicity data from an 8-day
carbon monoxide exposure of human subjects were
utilized (19). In that study, an 8-day exposure to 15 ppm
carbon monoxide resulted in 2.4% COHb and caused P wave
changes in the EKG. Therefore, the 7-day SMAC should be
established to prevent any EKG changes induceable by carbon
monoxide. It has been calculated that an 8-hour exposure of
exercising individuals to the EPA's 8-hour National Ambient
Air Quality Standard would yield a COHb of 1.6% (6). It is
reasoned that if 1.6% COHb is safe for the general population,
1.6% COHb should also be safe for astronauts. The 7-day
SMAC is the carbon monoxide exposure concentration that
would yield 1.6% COHb in a 7-day exposure. That SMAC
was calculated to be 10 ppm, applying the Skylab hemoglobin
concentration in the CFK equation.
The use of the hemoglobin concentration determined during
the Skylab missions in the 7-day SMAC calculation corrects
for the microgravity-induced reduction in red cells. Even
though cardiac arrhythmias were detected in the astronauts
(25) no c rrectl n made forduring the Skylab mission , o "o was
the potential synergistic effects of carbon monoxide and
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